Phase 1 Study of VENT-03: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers for Lupus Erythematosus

The primary objective of this study is to evaluate the **safety** and **tolerability** of orally administered VENT-03 in healthy volunteers. This is clinically relevant as it provides foundational data on the potential adverse effects and overall acceptability of the drug, which is crucial for determining its suitability for further clinical development in the treatment of **lupus erythematosus**. The study also aims to assess the **pharmacokinetics** and **pharmacodynamics** of VENT-03, as well as the effects of food and potential **drug-drug interactions**. These evaluations are essential for understanding the drug's absorption, distribution, metabolism, and excretion, as well as its mechanism of action and interaction with other substances, which are critical for optimizing dosing regimens and ensuring patient safety in future trials.

The clinical trial involves participants diagnosed with **Lupus erythematosus**. The study population includes both male and female subjects, with an age range categorized under code "3", which typically represents adults. The trial population selection criteria and the total number of participants have not been disclosed by the sponsor. The study includes a vulnerable population, indicating that special considerations may be necessary for their participation. Lifestyle factors such as diet, physical activity, and habits have not been specified. The sponsor has not provided detailed inclusion or exclusion criteria for this trial.

The clinical trial is a **Phase 1**, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, food effect, and drug-drug interaction of the investigational drug VENT-03 in healthy volunteers. The trial employs a **randomized, double-blind, placebo-controlled** design, incorporating both single and multiple ascending dose cohorts. The estimated duration of the trial spans from November 21, 2023, to July 29, 2025.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized to receive either the investigational drug or placebo. The study includes multiple follow-up visits to monitor safety and collect pharmacokinetic and pharmacodynamic data. The end-of-study visit will conclude the participant's involvement, ensuring all necessary data is collected and any adverse events are addressed.

The expected length of participant involvement will vary depending on the cohort assignment and dosing schedule. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, focusing on initial safety and efficacy assessments. The estimated recruitment start date is November 21, 2023, with an anticipated end date of July 29, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve the collection of preliminary data on the drug's effects, which may include biomarker levels or symptom improvement scores. The methods for measuring and analyzing these parameters are not specified, but Phase 1 trials generally employ validated scales and laboratory tests to ensure accurate and reliable data collection. The schedule for these assessments is typically aligned with the trial's timeline, ensuring that data is collected at relevant timepoints throughout the study duration.